Consolidated Statement Of Cash Flows

KYORIN Pharmaceutical Co., Ltd. - Filing #7257328

Concept As at
2025-03-31
2024-04-01 to
2025-03-31
2023-04-01 to
2024-03-31
As at
2024-03-31
As at
2023-03-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
4,824,000,000 JPY
4,695,000,000 JPY
Interest and dividends received
505,000,000 JPY
501,000,000 JPY
Interest paid
-173,000,000 JPY
-66,000,000 JPY
Income taxes paid
-1,317,000,000 JPY
-2,975,000,000 JPY
Net cash provided by (used in) operating activities
3,506,000,000 JPY
1,549,000,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-5,697,000,000 JPY
-5,778,000,000 JPY
Proceeds from sale of property, plant and equipment
42,000,000 JPY
0 JPY
Net cash provided by (used in) investing activities
-6,323,000,000 JPY
-3,187,000,000 JPY
Purchase of investment securities
-152,000,000 JPY
0 JPY
Other, net
-122,000,000 JPY
-509,000,000 JPY
Cash flows from financing activities
Dividends paid
-3,015,000,000 JPY
-3,013,000,000 JPY
Proceeds from long-term borrowings
20,000,000,000 JPY
JPY
Repayments of long-term borrowings
-10,200,000,000 JPY
-200,000,000 JPY
Net cash provided by (used in) financing activities
3,952,000,000 JPY
-3,347,000,000 JPY
Effect of exchange rate change on cash and cash equivalents
0 JPY
87,000,000 JPY
Net increase (decrease) in cash and cash equivalents
1,135,000,000 JPY
-4,897,000,000 JPY
Cash and cash equivalents
15,021,000,000 JPY
13,886,000,000 JPY
18,816,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.